With The Foundation of Gene Therapy, Pfizer Expands Rare Disease Research

December 8, 2014 6:02 PM

1 0

Pfizer proclaimed two deliberate verdicts to grow the organization’s rare disease research and development activities through the foundation of a gene therapy stage to explore potential medications for patients. Initially is a concurrence with Spark Therapeutics to create SPK-FIX, a program integrating a bio-built AAV vector for the potential treatment of Hemophilia B anticipated to enter Phase 1/2 clinical trials in the first half of 2015. Also, Pfizer has designated Michael Linden, Ph.d., Professor at King’s College London and Director of the University College London Gene Therapy Consortium, who will be with the organization for a two-year secondment to lead gene therapy research in the rare disease area.

“The basic insight of the biology of genetic rare diseases, coupled with advances in the engineering to tackle incapacitated infections as gene conveyance vehicles, give a ready chance to explore the next wave of potentially life changing therapies for patients,” said Mikael Dolsten, M.d., Ph.d., pr...

Read more

To category page